Real-Time lung cancer detection: new imaging technique could speed up diagnosis
NCT ID NCT07538947
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a special microscope called confocal laser endomicroscopy (CLE) can help doctors identify non-small cell lung cancer in real time during a biopsy. About 70 adults with suspected lung tumors will undergo standard bronchoscopy with added CLE imaging. Researchers will compare the CLE images to standard lab results to see if the new method is accurate enough to guide immediate surgical decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- confocal laser endomicroscopy (CLE) imaging
- What this could lead to
- If successful, this could give doctors a real-time tool to identify lung cancer during a biopsy, leading to faster surgical decisions and fewer repeat procedures.
- What could go wrong
- This is a small, early observational study (70 people) testing a new scoring system. It may not prove accurate enough for routine use, and the technique requires special equipment and training.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients at CHRU de Nancy scheduled for endobronchial navigation-guided biopsy due to suspected lung lesions
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient for whom endobronchial navigation-guided biopsy is indicated * Complete medical data (CLE images and histopathological results) Exclusion Criteria: * Persons referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code: * Individuals under 18 years of age * Adult persons subject to legal protection measures (guardianship, curatorship, or judicial protection) * Adult persons unable to express their consent * Persons deprived of liberty by judicial or administrative decision, and persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHRU Nancy
RECRUITINGNancy, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?
- Two-Drug combo takes aim at Hard-to-Treat lung cancer